NR4A1 and triple-negative breast carcinoma: Sacituzumab govitecan is a promising treatment option for patients with triple-negative breast cancer, a type of cancer that is difficult to treat due to the absence of hormone receptors, specifically human epidermal growth factor receptor 2.